Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less
Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system th ....Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system through regular clinical visits, hospitalisation and employment downtime. The global market for the treatment of COPD is currently more than $8 billion and is expected to increase substantially. The positioning of an Australian pharmaceutical company at the forefront of COPD/CF treatment will have significant national benefits for patients, the health system, and research infrastructure in the field.Read moreRead less